Exhibit B

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Attorney Docket Number 792-A-PCT-US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Application Number 10/650,365

Filing Date August 28, 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

Filing Date	August 28, 2003
First Named Inventor	Guangwen WEI
Art Unit	1646
Examiner Name	Bruce D. Hissong

			U. S. PATEN	DOCUMENTS					
Examiner Initials*	Cite No.1	Cite No. ¹	Cite No. ¹	Cite No. ¹	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	^{US-} 6,114,145	09-05-2000	OLSEN et al.					
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							

Cite No. ¹		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Т
2	WO 2005/034853 A2	04-21-2005	HUIYANGTECH (INC.) USA		
3	AU 2003248419	11-06-2003	WEI et al.		
4	CN 1375502A	11-23-2002	YAO et al.		
5	CN 1478545A	03-03-2004	GAO et al.		Г
					L
	3 4	2 WO 2005/034853 A2 3 AU 2003248419 4 CN 1375502A	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) WO 2005/034853 A2 04-21-2005 AU 2003248419 11-06-2003 CN 1375502A 11-23-2002	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known) 2 WO 2005/034853 A2 04-21-2005 HUIYANGTECH (INC.) USA 3 AU 2003248419 11-06-2003 WEI et al. 4 CN 1375502A 11-23-2002 YAO et al.	Country Code ³ "Number ⁴ "Kind Code ³ (if known) WO 2005/034853 A2 04-21-2005 HUIYANGTECH (INC.) USA AU 2003248419 11-06-2003 WEI et al. CN 1375502A 11-23-2002 YAO et al.

Examiner		Date	,
Signature		Considered	
	·		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu					Complete if Known			
				Application Number	10/650,365			
INF	ORMATION	DIS	CLOSURE	Filing Date	August 28, 2003			
STA	STATEMENT BY APPLICANT		First Named Inventor	Guangwen WEI				
	(Use as many she	efs as n	ereccani)	Art Unit	1646			
	quad de many en e	0.0 40 11		Examiner Name	Bruce D. Hissong			
Sheet	2	of	4	Attorney Docket Number	792-A-PCT-US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Written Opinion of the International Searching Authority for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2004.	
	4	International Search Report for International Application No. PCT/US04/28068, filed August 26, 2004 for HUIYANGTECH (USA) INC., dated March 4, 2005.	
	8	Ivan AMATO, January 22, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.	
	9	AUSUBEL et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," from Short Protocols in Molecular Biology, 4th ed., p. 10-1 to 10-8.	
	10	CINATL et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.	
	11	DAY et al., 1992, "Engineered disulfide bond greatly increases specific activity of recombinant murine interferon-beta," Journal of Interferon Res., 12: 139-143.	
	12	DUAN et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.	
	13	HIGGINS et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715.	
	14	HOLLAND, C.C. and T.L. WRIGHT, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1).	
,	15	NACKLEY, A.G. et al., December 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	NFORMATION D				Complete if Known
				Application Number	10/650,365
INF	ORMATION	I DIS	CLOSURE	Filing Date	August 28, 2003
STA	STATEMENT BY APPLICANT		First Named Inventor	Guangwen WEI	
	(Use as many she	note se n	acassand	Art Unit	1646
	tose as many sine	: CD C3 //	ecessary)	Examiner Name	Bruce D. Hissong
Sheet	3	of	4	Attorney Docket Number	792-A-PCT-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	NASOFF et al., 1999, "High-level expression of human genes in E. coli," Expression, 6(2): 10-11.	
	17	PYRC, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders – Drug Targets, 7:59-66.	
•	18	ZHAO, Z. et al., 2003, "Description and clinical treatment of an early outbreak of Severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720.	
	19	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated April 3, 2007.	
	20	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated June 14, 2007.	
	21	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,956 (Atty. Dkt. #792-C-US), Filed August 26, 2004, Dated December 15, 2006.	
	22	Advisory Action Before the Filing of an Appeal Brief for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated May 22, 2007.	
	23	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 9, 2007.	
	24	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated February 9, 2007.	
	25	U.S. Office Action for Guangwen WEI, U.S. Serial No. 10/928,474 (Atty. Dkt. #795-A-US), Filed August 26, 2004, Dated August 22, 2006.	

Examiner	,	Date	
Signature	,	Considered	· ·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE FILE STATEMENT BY APPLICANT		Complete if Known			
				Application Number	10/650,365
				Filing Date	August 28, 2003
STA	STATEMENT BY APPLICANT		First Named Inventor	Guangwen WEI	
	(Use as many she	ets as i	necessary)	Art Unit	1646
	(odo do many one			Examiner Name	Bruce D. Hissong
Sheet	4	of	4	Attorney Docket Number	792-A-PCT-US

	1 20	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	26	U.S Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 1, 2007.	
	27	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated November 27, 2006.	•
	28	U.S. Office Action for Guangwen WEI, U.S. Serial No. 11/077,813 (Atty. Dkt. #1005-A-US), Filed March 10, 2005, Dated August 8, 2006.	
	29	U.S Office Action for Guangwen WEI, U.S. Serial No. 10/927,975 (Atty. Dkt. #796-A-US), Filed August 26, 2004, Dated September 19, 2007.	

Examiner	Date	
Signature	Considered	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.